A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity
NCT ID: NCT06717425
Last Updated: 2025-11-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE2
263 participants
INTERVENTIONAL
2024-12-09
2025-11-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Obesity
NCT04707313
A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or Obese
NCT05677867
Safety, Pharmacokinetics and Pharmacodynamics Study to Evaluate BMS-830216 in Obese Subjects
NCT00909766
Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health Conditions
NCT06867718
A Long-Term Study To Examine The Effects Of CP-945,598 On Weight Loss And Safety
NCT00375401
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PF-07976016 Dose 1
PF-07976016
Taken once daily
PF-07976016 Dose 2
PF-07976016
Taken once daily
PF-07976016 Dose 3
PF-07976016
Taken once daily
Placebo
Placebo
Taken once daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PF-07976016
Taken once daily
Placebo
Taken once daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body Mass Index ≥30.0 kg/m2 at Visit 1, with stable body weight, defined as \<5 kg change in the 12 weeks before Visit 1
* Eligible and willing to receive required background medicine
* Willing and able to comply with all study procedures
Exclusion Criteria
* Use of any prohibited prior or concomitant medication(s)
* Presence of specified abnormalities on diagnostic assessments including clinical laboratory tests at Visit 1.
18 Years
74 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Anaheim Clinical Trials, LLC
Anaheim, California, United States
Artemis Institute for Clinical Research
San Diego, California, United States
Clinical & Translational Research Center
Aurora, Colorado, United States
University of Colorado Anschutz Medical Campus
Aurora, Colorado, United States
Westside Center for Clinical Research
Jacksonville, Florida, United States
New Horizon Research Center
Miami, Florida, United States
Renstar Medical Research
Ocala, Florida, United States
Renstar Medical Research
Ocala, Florida, United States
St Johns Center for Clinical Research
Saint Augustine, Florida, United States
Rophe Adult and Pediatric Medicine/SKYCRNG
Union City, Georgia, United States
East-West Medical Research Institute
Honolulu, Hawaii, United States
Cotton O'Neil Diabetes & Endocrinology
Topeka, Kansas, United States
L-MARC Research Center
Louisville, Kentucky, United States
Pennington Biomedical Research Center
Baton Rouge, Louisiana, United States
StudyMetrix Research
City of Saint Peters, Missouri, United States
Rochester Clinical Research, LLC
Rochester, New York, United States
Accellacare - Wilmington
Wilmington, North Carolina, United States
AMR Clinical
Norman, Oklahoma, United States
Cornerstone Nutrition and Diabetes
Norman, Oklahoma, United States
Capital Area Research, LLC
Camp Hill, Pennsylvania, United States
Elligo Clinical Research Center
Austin, Texas, United States
Texas Diabetes & Endocrinology, P.A.
Austin, Texas, United States
Velocity Clinical Research, Dallas
Dallas, Texas, United States
UT Southwestern Medical Center
Dallas, Texas, United States
Consano Clinical Research, LLC
Shavano Park, Texas, United States
Chrysalis Clinical Research
St. George, Utah, United States
Southwest Internal Medicine, PC
St. George, Utah, United States
Selma Medical Associates
Winchester, Virginia, United States
Ocean West Research Clinic
Surrey, British Columbia, Canada
Dawson Clinical Research Inc.
Guelph, Ontario, Canada
The Wharton Medical Clinic Clinical Trials Inc.
Hamilton, Ontario, Canada
Milestone Research Inc.
London, Ontario, Canada
Canadian Phase Onward
Toronto, Ontario, Canada
Centrum Zdrowia Metabolicznego Pawel Bogdanski
Poznan, Greater Poland Voivodeship, Poland
Medicome Sp. z o. o.
Oświęcim, Lesser Poland Voivodeship, Poland
Ekamed
Lublin, Lublin Voivodeship, Poland
Centrum Badan Klinicznych PI-House sp. z o.o.
Gdansk, Pomeranian Voivodeship, Poland
Centrum Medyczne Pratia Gdynia
Gdynia, Pomeranian Voivodeship, Poland
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-513679-42-00
Identifier Type: REGISTRY
Identifier Source: secondary_id
C5541010
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.